SPL026

DRUG2 trials

Sponsors

Small Pharma Ltd

Conditions

Major Depressive Disorder

Phase 1

SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients

CompletedNCT04673383

Small Pharma LtdMajor Depressive Disorder

Start: 2021-02-04End: 2022-12-22Updated: 2024-03-27

SPL026 With or Without SSRIs in Participants With MDD

CompletedNCT05553691

Small Pharma LtdMajor Depressive Disorder

Start: 2022-12-13End: 2023-08-03Updated: 2024-06-14

Related Papers

A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial.

2026-02-16

Safety and tolerability of NN-dimethyltryptamine (DMT) in healthy volunteers and Major Depressive Disorder (MDD) patients: A systematic review of early-phase clinical trials.

2025-06-07

Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial

Frontiers in Psychiatry2024-01-1114 citations

Pharmacokinetics of N,N-dimethyltryptamine in Humans

European Journal of Drug Metabolism and Pharmacokinetics2023-04-2245 citations